ArticleMolecular cancer therapeutics2022

RP-3500: A Novel, Potent, and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors.

Anne Roulston et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.